Arcus Biosciences (RCUS) officer eyes sale after June plan trades

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) is the issuer for a Rule 144 notice filed for the planned sale of its common stock by officer Alexander Azoy. The filing lists 2,827 shares of common stock, with an aggregate market value of $83,453.04, to be sold through Morgan Stanley Smith Barney LLC, with the shares to be issued upon the exercise of stock options for cash. The notice also references prior 10b5-1 plan sales of 2,562 shares for $66,023.76 on June 1, 2026.

Key Figures

Shares to be sold: 2,827 shares of common stock Aggregate market value of planned sale: $83,453.04 Shares sold in past 3 months: 2,562 shares of common stock +2 more

5 metrics

Shares to be sold 2,827 shares of common stock Planned Rule 144 sale by officer Alexander Azoy

Aggregate market value of planned sale $83,453.04 Value of 2,827 Arcus Biosciences shares listed in the Form 144

Shares sold in past 3 months 2,562 shares of common stock 10b5-1 sales by Alexander Azoy on 06/01/2026

Aggregate value of past 3-month sales $66,023.76 Proceeds from 2,562 shares sold on 06/01/2026

Planned sale date 08/21/2026 Date associated with the securities to be sold and market information

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for ALEXANDER AZOY 3928 Point Eden Way Hayward CA 94545"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 08/21/2026 | Exercise of Stock Options | Issuer"

FAQ

What does the Form 144 filing disclose for Arcus Biosciences (RCUS)?

The filing discloses a planned Rule 144 sale of 2,827 shares of Arcus Biosciences common stock by officer Alexander Azoy, with an aggregate market value of $83,453.04, to be sold through Morgan Stanley Smith Barney LLC after exercising stock options for cash.

Who is selling Arcus Biosciences (RCUS) shares in this Form 144?

Officer Alexander Azoy is the person for whose account the Arcus Biosciences common stock is to be sold under Rule 144, using Morgan Stanley Smith Barney LLC as the broker.

How many RCUS shares are proposed to be sold and at what value?

The Form 144 lists 2,827 common shares of Arcus Biosciences with an aggregate market value of $83,453.04 as the securities proposed to be sold under Rule 144.

What is the source of the RCUS shares to be sold by Alexander Azoy?

The shares are to be issued upon the exercise of stock options by Alexander Azoy, with the exercise consideration in cash, and then sold as disclosed in the Form 144.

What prior sales are reported for Alexander Azoy in the past 3 months for RCUS?

The filing reports 10b5-1 plan sales of Arcus Biosciences common stock by Alexander Azoy of 2,562 shares on 06/01/2026 for aggregate proceeds of $66,023.76 in the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:37 PM Accepted by SEC EDGAR 08/21/2026 - 04:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001771961
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcus Biosciences, Inc.
SEC File Number	001-38419
Address of Issuer	3928 Point Eden Way Hayward CALIFORNIA 94545
Phone	5106946200
Name of Person for Whose Account the Securities are To Be Sold	ALEXANDER AZOY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2827	83453.04	127333376	08/21/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2026	Exercise of Stock Options	Issuer			2827	08/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ALEXANDER AZOY 3928 Point Eden Way Hayward CA 94545	Common	06/01/2026	2562	66023.76

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Alexander Azoy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)